Updated efficacy data in 34 evaluable patients with a chemotherapy-free regimen; randomized Part C will add BI-1808 to the ...

When the body treats a therapeutic antibody as foreign, it produces anti-drug antibodies that can blunt the drug’s effect, change how it moves through the body and raise safety concerns. The FDA’s ...

A randomized phase 2a trial found the SARS-CoV-2 monoclonal antibody AER002 safe but ineffective for Long COVID overall, though post-hoc analysis suggested benefit in patients with low baseline ...

APRIL suppression sustained through 12 weeks, supporting Q12W dosing interval ~70% reduction in Gd-IgA1 at 12 weeks ~33-day half-life. NAVIGATE-2 Phase 2 trial enrolling ...

Researchers have mapped conserved epitopes on the sarbecovirus spike protein that allow three monoclonal antibodies to ...

Investigational tovecimig combined with paclitaxel significantly improved the response rate and progression-free survival (PFS) in patients with previously treated advanced or metastatic biliary tract ...

"Dupixent," a massive mega-blockbuster with annual sales exceeding $13 billion. The golden duo of Sanofi and Regeneron, who ...

Atacicept and sibeprenlimab were granted accelerated FDA approval based on interim trial findings that showed a reduction in proteinuria in adults with IgA nephropathy. As a condition of the ...

Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the publication of Phase 3 RAINIER results for povetacicept in the New England Journal of Medicine (NEJM), presentation of these data ...

Can I no longer use new drugs after starting dialysis?As you continue treatment for myeloma, your kidney function may decline ...

REGN20423, a clinical-stage long-acting IL-13 monoclonal antibody invented and developed by Regeneron, is added to the Alliance, along with a long-acting IL-4xIL-13 bispecific and two other ...

Ivonescimab is an investigational therapy that is not approved by any regulatory authority in Summit's license territories, ...